DRG Market Assessment reports

Clarivate Epidemiology’s coverage of influenza comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report diagnosed influenza event rates for each country…

Clarivate Epidemiology’s coverage of influenza comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report diagnosed influenza event rates for each country…

Clarivate Epidemiology’s coverage of influenza comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report diagnosed influenza event rates for each country…

Clarivate Epidemiology’s coverage of influenza comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report diagnosed influenza event rates for each country…

Clarivate Epidemiology’s coverage of influenza comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed influenza event for each country,…

Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…

Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature pharmaceutical markets worldwide. We report the…

Renal inflammation associated with systemic lupus erythematosus (SLE), also known as lupus nephritis (LN), is among the most serious manifestations of the disease. Until 2020, no therapy was…

Clarivate Epidemiology’s coverage of Crohn’s disease (CD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CD…

Clarivate Epidemiology’s coverage of Crohn’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed prevalence…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations, covering 171 countries and…

The small-cell lung cancer (SCLC) treatment landscape is dominated by chemotherapy and chemoradiotherapy. The immune checkpoint inhibitors Tecentriq (Roche; FDA approved in 2019) and Imfinzi (…